イタリア - イタリア語 - Ministero della Salute

boehringer ingelheim vetmedica gmbh - pimobendan - pimobendan - 10 milligrammo (i), pimobendan - 1.25 milligrammo (i), pimobendan - 2.5 milligrammo (i), pimobendan - 5 milligrammo (i), pimobendan - 10 mg, pimobendan - 5 mg, pimobendan - 1.25 mg, pimobendan - 2.5 mg - pimobendan

イタリア - イタリア語 - Ministero della Salute

cp-pharma handelsgesellschaft mbh - pimobendan - orale - pimobendan - 2.5 milligrammo (i), pimobendan 1,25 mg - pimobendan - cani

欧州連合 - イタリア語 - EMA (European Medicines Agency)

sandoz gmbh - adalimumab - arthritis, rheumatoid; arthritis, psoriatic; spondylitis, ankylosing; uveitis; hidradenitis suppurativa; colitis, ulcerative; arthritis, juvenile rheumatoid; crohn disease; skin diseases, papulosquamous - immunosoppressori - rheumatoid arthritishyrimoz in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. hyrimoz può essere somministrato come monoterapia in caso di intolleranza al metotressato o quando il trattamento continuato con metotressato è inappropriato. adalimumab ha dimostrato di ridurre il tasso di progressione del danno articolare misurato da x-ray e di migliorare la funzione fisica, quando somministrato in combinazione con metotressato. juvenile idiopathic arthritis- polyarticular juvenile idiopathic arthritishyrimoz in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). hyrimoz può essere somministrato come monoterapia in caso di intolleranza al metotressato o quando il trattamento continuato con metotressato è inappropriato. adalimumab non è stato studiato in pazienti di età inferiore a 2 anni. - enthesitis-related arthritishyrimoz is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. axial spondyloarthritis- ankylosing spondylitis (as)hyrimoz is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. - axial spondyloarthritis without radiographic evidence of ashyrimoz is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and / or mri, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs. psoriatic arthritishyrimoz is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. adalimumab ha dimostrato di ridurre il tasso di progressione del danno articolare periferico misurata da x-ray nei pazienti con poliarticolare simmetrica sottotipi della malattia e di migliorare la funzione fisica. psoriasishyrimoz is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasishyrimoz is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)hyrimoz is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy. crohn’s diseasehyrimoz is indicated for treatment of moderately to severely active crohn’s disease in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and / or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's diseasehyrimoz is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and / or an immunomodulator, or who are intolerant to or have contraindications for such therapies.  paediatric ulcerative colitishyrimoz is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. ulcerative colitishyrimoz is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitishyrimoz is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitishyrimoz is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

イタリア - イタリア語 - Ministero della Salute

alfasan nederland b.v. - pimobendan - pimobendan - 5 milligrammo (i), pimobendan - 2.5 milligrammo (i), pimobendan - 1.25 milligrammo (i), pimobendan - 15 milligrammo (i) - pimobendan

イタリア - イタリア語 - Ministero della Salute

eurovet animal health b.v. - pimobendan - pimobendan - 5 milligrammo (i), pimobendan - 2.5 milligrammo (i), pimobendan - 10 milligrammo (i), pimobendan - 1.25 milligrammo (i), pimobendan - 1.25 mg, pimobendan - 2.5 mg, pimobendan - 10 mg, pimobendan - 5 mg - pimobendan

スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

jntl consumer health ii (switzerland) gmbh - minoxidilum - soluzione - minoxidilum 20 mg, propylenglycolum 207.20 mg, ethanolum 96 per centum 504.6375 mg, aqua purificata, ad solutionem pro 1 ml. - alopecia androgenetica - synthetika

スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

jntl consumer health ii (switzerland) gmbh - minoxidilum - soluzione - minoxidilum 50 mg, propylenglycolum 518 mg, ethanolum 96 per centum 252.32 mg, aqua purificata, ad solutionem pro 1 ml. - alopecia androgenetica - synthetika

イタリア - イタリア語 - AIFA (Agenzia Italiana del Farmaco)

johnson & johnson s.p.a. - minoxidil - minoxidil

スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

pierre fabre pharma sa - minoxidilum - soluzione per l'applicazione sulla pelle - minoxidilum 20 mg, ethanolum 96 per centum 443.9 mg, gammadexum, propylenglycolum 50 mg, aqua purificata, ad solutionem pro 1 ml. - alopecia androgenetica - synthetika

イタリア - イタリア語 - AIFA (Agenzia Italiana del Farmaco)

difa cooper s.p.a. - minoxidil - minoxidil